Stryker's second quarter revenue rose to $6.6B with 9.0% organic growth, signaling a strong post-cyberattack recovery.

Stryker reported second quarter 2026 revenue of $6.6 billion, up 9.4% year-over-year, and reported EPS of $3.30. Adjusted EPS of $3.69 increased 17.9% and surpassed analyst expectations of $3.46, as the company showed significant recovery from a cyber incident that impacted the prior quarter.

Key Highlights

• Organic net sales increased 9.0%, indicating a strong recovery from the prior quarter's cyber incident and surpassing the 8.75% consensus estimate.
• Both major segments posted robust results, with MedSurg and Neurotechnology organic sales up 9.2% and Orthopaedics organic sales growing 8.6%.
• Stryker narrowed its full-year 2026 outlook, now expecting organic sales growth of 8.3% to 9.3% and adjusted EPS between $14.95 and $15.10.